Vaccines for neglected and emerging diseases in Brazil by 2030
The "valley of death" and opportunities for RD&I in Vaccinology 4.0
Datos Bibliográficos
| ID | 5166103 |
|---|---|
| Autores | Akira Homma (0000-0002-4641-8491, Fundação Oswaldo Cruz), Marcos Da Silva Freire (0000-0002-4723-8994, Fundação Oswaldo Cruz), Cristina Possas (0000-0002-2886-2812, Fundação Oswaldo Cruz) |
| Año | 2020 |
| Volumen | 36 |
| Número | suppl 2 |
| Páginas | e00128819-e00128819 |
| Fecha de publicación | 2020-01-01 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | Cadernos de Saude Publica (JOURNAL) |
| Identificadores de la revista | ISSN: 0102-311X • E-ISSN: 1678-4464 |
| Editorial | FapUNIFESP (SciELO) (PUBLISHER) |
| DOI | 10.1590/0102-311x00128819 |
| PMID | 33111747 |
| OpenAlex | W3096457848 |
| SCIELO_PID | S0102-311X2020001403002 |
| Idioma | EN |
| Citas recibidas | 5 |
| Referencias citadas | 19 |
We examine the implications of the very low competitiveness of the Brazilian vaccine RD&I system, which precludes the development of all the important vaccines required by the National Immunization Program (NIP), severely impacting the healthcare of the population. In a country dramatically affected by COVID-19 pandemic and by an exponential increase in emerging and neglected diseases, particularly the poor, these RD&I constraints for vaccines become crucial governance issues. Such constraints are aggravated by a global scenario of limited commercial interest from multinational companies in vaccines for neglected and emerging diseases, which are falling into a "valley of death," with only two vaccines produced in a pipeline of 240 vaccines. We stress that these constraints in the global pipeline are a window of opportunity for vaccine manufacturers in Brazil and other developing countries in the current paradigm transition towards Vaccinology 4.0. We conclude with recommendations for a new governance strategy supporting Brazilian public vaccine manufacturers in international collaborations for a sustainable national vaccine development and production plan by 2030
Business · Coronavirus disease 2019 (COVID-19) · Development economics · Economic growth · Economics · Environmental health · Global health · Health care · Infectious disease (medical specialty) · Multinational corporation · Pandemic · Political science · Population · Public health · Window of opportunity · Engineering · Finance · Innovation and Socioeconomic Development · Medicine · Vaccine Coverage and Hesitancy · Viral Infections and Outbreaks Research
Overcoming enduring inequalities in Global Value Chains? Interpreting the case of Brazil’s Covid-19 vaccine supply through a chess metaphor
Advancing sustainable development goals through immunization
Dependency, Capacity, and Agency
Reply to the Letter to the Editors by Beirão
Brazil must complete the cycle in vaccine development
| Obras citantes distintas | 5 |
|---|---|
| Citas por año | 1 |
| Intervalo de citas | 2021 - 2024 (4) |
| Velocidad de citación | recent |
| Altamente citado | No |
| Tipos de cita | Neutras: 5 |